ArticleJournal of the American Academy of Dermatology2018
Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy.
Article in Journal of the American Academy of Dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review.American journal of clinical dermatology · 2023Pooled it
- Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations.American journal of clinical dermatology · 2025Review
- Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T-Cell Lymphoma: A Real-World Single-Center Experience.The Journal of dermatology · 2025Article
- Case Report: Cutaneous T-cell lymphoma associated with biologic therapy: three cases and a literature review.Frontiers in medicine · 2025Article
- Drug- and Vaccine-Induced Cutaneous T-Cell Lymphoma: A Systematic Review of the Literature.Journal of skin cancer · 2025Review
- Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management.JAAD case reports · 2024Article
- Review
- Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis.Dermatologic therapy · 2024Article
- Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies.Dermatology and therapy · 2024Review
- Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma.Dermatology and therapy · 2023Article
- Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion.American journal of clinical dermatology · 2023Review
- Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor.Acta dermato-venereologica · 2022Article
- Partial remission of advanced untreated Sézary syndrome after COVID-19.JAAD case reports · 2022Article
- Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series.The British journal of dermatology · 2022Article
- Understanding the enigmatic association between mycosis fungoides and psoriasis: Report of two cases and review of the literature.Metabolism open · 2021Review
- Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL).Postepy dermatologii i alergologii · 2021Review
- Evaluation of Melanocyte Loss in Mycosis Fungoides Using SOX10 Immunohistochemistry.Dermatopathology (Basel, Switzerland) · 2021Article
- Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report.World journal of gastrointestinal oncology · 2021Article
- Nivolumab-associated cutaneous T-cell lymphoma.JAAD case reports · 2021Article
- The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.Journal of the American Academy of Dermatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCutaneous lymphoma diagnosed after anti-tumor necrosis factor-α therapy (anti-TNF-α) has been reported in the literature, yet a clear link between both events remains elusive.
objectiveTo review our experience with cutaneous lymphoma diagnosed during or after the use of anti-TNF-α therapies.
methodsThis is a multicenter retrospective study and a literature review.
resultsA total of 22 cases, including 20 cutaneous T-cell lymphomas (CTCLs) and 2 cutaneous B-cell lymphomas, were identified. In the CTCL group, 75% of the patients received an anti-TNF-α agent for a presumed inflammatory skin condition. Mycosis fungoides and Sézary syndrome were the most common subtypes of CTCL diagnosed. Advanced disease (stage IIB to IVA) was commonly seen at time of diagnosis and required aggressive therapy, including stem cell transplant in 3 patients; 2 patients in whom cutaneous B-cell lymphomas was diagnosed had an indolent course. A total of 31 cases were gathered from a literature search. LIMITATIONS: This is a retrospective study.
conclusionsOur findings suggest that the disease of most of the identified patients was misdiagnosed as psoriasis or eczema; therefore, a comprehensive morphologic and molecular review of skin biopsy specimens and peripheral blood samples should be considered before initiation of anti-TNF-α therapy in patients with poorly defined dermatitis or atypical presentations of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.